Skip to main content
OpenTrials
Completed

NCT Number: NCT05753371

Bioequivalence Study of Metformin Hydrochloride 500 mg Film-Coated Tablets in Indonesia Healthy Subject

The objective of this present study was to investigate whether Glufor® 500 (metformin hydrochloride 500 mg) film-coated tablets manufactured by PT. Pyridam Farma Tbk is bioequivalent to its reference product, Glucophage® 500 mg film-coated tablets manufactured by PT. Merck Tbk, Indonesia under licensed Merck Sante SAS, France.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–52 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

PT Pharma Metric Labs

Jakarta Pusat, DKI Jakarta, 10520, Indonesia

About this study

Twenty-four subjects were given a single dose of 500 mg Metformin film-coated tablet of either formulation (test or reference) with 240 mL of a 20% glucose solution in water.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

The inclusion criterias were healthy male or female subjects who/with:

  • had read the subject information and signed informed consent documents
  • age range from 18 - 55 years
  • body mass index between 18 - 25 kg/m2
  • had a normal electrocardiogram
  • had the blood pressure within normal range (systolic 90-120 mmHg and diastolic 60-80 mmHg)
  • had the heart rate within normal range (60 - 100 bpm)
  • had absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluation, medical history or physical examination during screening.

Exclusion criteria

s

The subjects' exclusion criterias for the study were:

  • those who were pregnant and/or nursing women.
  • those with history of contraindication or hypersensitivity to metformin or other antidiabetic agent or other ingredients in the study products or a history of serious allergic reaction to any drug, a significant allergic disease, or allergic reaction.
  • those with a history or presence of medical condition which might significantly influence the pharmacokinetic of the study drug, e.g. chronic gastrointestinal disease, diarrhea, gastric surgery, renal insufficiency, hepatic dysfunction or cardiovascular disease.
  • those with a history or presence of any coagulation disorder or clinically significant hematology abnormalities.
  • those who were using any medication (prescription or non-prescription drug, food supplement, herbal medicine), particularly the medication known to affect the pharmacokinetic of the study drug, within one week prior to the drug administration day.
  • those who had participated in any clinical study within 3 months prior to the study (<90 days).
  • those who had donated or lost 300 ml (or more) of blood within 3 months prior to the study.
  • those who smoked more than 10 cigarettes a day
  • those with a history of travelling to another city within the last 14 days
  • those with a history of direct contact with a COVID-19 positive person in the subject's neighbourhood
  • those with a history or present of sore throat, fever (with temperature more than 37°C) or dyspnea with in the last 14 days
  • those who are positive to SARS CoV-2 antigen test
  • those who were positive to HIV, HBsAg, and HCV tests (to be kept confidential).
  • those with a history of drug or alcohol abuse within 12 months prior to screening for this study.
  • those who were unlikely to comply with the protocol, e.g uncooperative attitude, inability to return for follow up visits, poor venous access.

Treatment and study plan

Metformin Hydrochloride 500 MG

Drug

Metformin is an antihyperglycemic drug used in the management of type-2 diabetes. Metformin hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

Primary outcomes

  1. Geometric Mean Ratio

    Time frame: 0-24 hours post dose

    The ratio between maximum concentration of test drug and reference drug after drug administration

  2. Geometric Mean Ratio

    Time frame: 0-24 hours post dose

    The ratio between area under curve from 0 to 24 hours of test drug and reference drug

Secondary outcomes

  1. Pharmacokinetics Parameter

    Time frame: 0-24 hours post dose

    Maximum plasma concentration (Cmax)

  2. Pharmacokinetics Parameter

    Time frame: 0-24 hours post dose

    Area Under Curve from 0 to 24 hours (AUCt)

Sponsors and collaborators

Lead sponsor

PT. Pyridam Farma Tbk

Industry

Collaborators

  • PT Pharma Metric Labs

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Mar 3, 2023
Registry last updated
Mar 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.